ozempic break
Stopping Ozempic Abruptly Sends Prescription Weight Loss Back
The FDA is proposing to exclude semaglutide, tirzepatide and liraglutide from the 503B bulk compounding list, effectively limiting unauthorized compounded GLP-1 weight-loss drugs. This move follows concerns about safety, pricing and the rapid expansion of GLP-1 prescriptions across the United States. Medical Disclaimer: This article is for informational purposes only